Background: Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the United States. Understanding healthcare utilization associated with medically attended (MA) RSV lower respiratory tract infection (LRTI) might inform research priorities aimed at reducing RSV-associated pediatric morbidity. We described healthcare utilization during acute MA RSV LRTI episodes within a geographically diverse cohort of infants in the United States.

Methods: We created retrospective cohorts of infants born in the United States from July 1, 2016 through February 29, 2020 in each of three de-identified insurance claims datasets: Merative MarketScan Commercial Claims and Encounters, Multi-State MarketScan Medicaid, and Optum's de-identified Clinformatics ® Data Mart. We identified infants' first MA RSV LRTI diagnosis during their first RSV season and followed them for 7 subsequent days to record outpatient, emergency department, and inpatient hospital utilization. We calculated the number of outpatient visits, emergency department visits, and inpatient hospital stays occurring during this acute episode and estimated the proportion of episodes involving ≥ 2 visits to a given healthcare setting.

Results: In the CCAE database, we identified 25,409 acute MA RSV LRTI episodes under the specific RSV definition and 69,068 under the sensitive definition. In the MDCD database, these totals were 67,357 and 170,744, while in the CDM database, they were 12,402 and 31,363, respectively. Across data sources, 34%-69% of infants' first acute MA RSV LRTI episodes involve 2 or more visits to a healthcare setting within 7 days. The percentage of episodes involving at least 2 visits ranged from 34-62% among healthy term infants, 38-65% for Palivizumab-eligible infants, and 38-69% for infants with other comorbidities.

Conclusions: Within a week of their first MA RSV LRTI diagnosis, infants frequently experience at least 2 visits to one or more healthcare settings, regardless of their comorbidity profile. The percentage of MA RSV LRTI episodes involving at least 2 visits to a healthcare setting may vary by insurance claims database, even between commercial payers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809781PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0313573PLOS

Publication Analysis

Top Keywords

rsv lrti
24
lrti episodes
16
visits healthcare
16
healthcare utilization
12
united states
12
acute rsv
12
episodes involving
12
rsv
10
utilization acute
8
medically attended
8

Similar Publications

Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus.

JAMA Netw Open

March 2025

Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale School of Medicine, New Haven, Connecticut.

Importance: Nirsevimab, a long-acting monoclonal antibody, demonstrated efficacy against respiratory syncytial virus (RSV)-associated lower respiratory tract infections (LRTI) in clinical trials. Postlicensure monitoring is essential to confirm these benefits in clinical settings.

Objective: To estimate the effectiveness of nirsevimab against medically attended RSV infections in infants and to assess how effectiveness varies by disease severity, dosage, and time since immunization.

View Article and Find Full Text PDF

: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants and the leading cause of infant hospitalization in the U.S. and worldwide.

View Article and Find Full Text PDF

Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants.

NEJM Evid

March 2025

EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for the Safety of Medicines and Health Products (ANSM), French National Fund for Health Insurance (CNAM), Saint-Denis, France.

Background: In pivotal trials, nirsevimab showed promising efficacy in reducing hospitalizations for respiratory syncytial virus-associated lower respiratory tract infections (RSV-LRTIs). Nirsevimab's real-world effectiveness needs to be assessed.

Methods: This population-based study used the French National Health Data System.

View Article and Find Full Text PDF

Background: Respiratory syncytial virus (RSV) is one of the main causes of morbidity in infants and young children worldwide. Current data on RSV-associated disease burden in Germany before the introduction of new immunization strategies is lacking.

Methods: The PAPI study is a multicenter, prospective surveillance study of lower respiratory tract infections (LRTI) in children aged ≤ 24 months in Germany.

View Article and Find Full Text PDF

Introduction: Worldwide, respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTIs) and hospital admissions among infants and young children. The COVID-19 pandemic changed the epidemiology and clinical patterns of respiratory viruses other than severe acute respiratory syndrome coronavirus 2. Argentina introduced the RSV maternal vaccine in 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!